Therefore, dual SGLT1 and SGLT2 inhibitors, such as sotagliflozin (SOTA) and LX-2761, are currently being investigated as potential drugs for the treatment of diabetes (Figure 5) [43,46,52]. This evidence concerns the gene SLC5A2 and diabetes mellitus.